Dermata Therapeutics(DRMA)
$0.72+0.00 (+0.14%)
DRMA
Dermata Therapeutics financials statements
$0.72
At close:+0.00 (+0.14%)
Want to see DRMA full AI Analyst Report?
Dermata Therapeutics (DRMA) Ratios
160 Followers
Dermata Therapeutics Ratios
DRMA's free cash flow for Q2 2026 was $-2.53M. For the 2026 fiscal year, DRMA's free cash flow was decreased by $-110.67K and operating cash flow was $-2.42M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.79 | 1.79 | 4.91 | 7.53 | 7.66 |
| Quick Ratio | 4.79 | 1.79 | 4.91 | 7.53 | 7.66 |
| Cash Ratio | 4.59 | 1.60 | 4.58 | 6.76 | 7.12 |
| Solvency Ratio | -4.61 | -6.23 | 0.15 | -10.42 | -5.21 |
| Operating Cash Flow Ratio | -4.73 | -5.66 | -3.95 | -9.57 | -3.75 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 6.22M | $ 1.56M | $ 6.36M | $ 6.02M | $ 10.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.26 | 2.26 | 1.26 | 1.15 | 1.15 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 151.18 | -172.25 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 152.18 | -172.25 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | -0.92 | 0.88 |
| Net Debt to EBITDA | 0.97 | 0.26 | -30.09 | 0.65 | 1.37 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 97.23% | 98.20% | 96.93% | 99.34% | 100.58% |
| Return on Assets (ROA) | -96.12% | -347.70% | -97.70% | -138.40% | -67.98% |
| Return on Equity (ROE) | -121.45% | -787.11% | -122.66% | -159.60% | -78.19% |
| Return on Capital Employed (ROCE) | -124.91% | -801.57% | -126.55% | -160.66% | -77.74% |
| Return on Invested Capital (ROIC) | -124.91% | -801.57% | -126.55% | -160.66% | -77.74% |
| Return on Tangible Assets | -96.12% | -347.70% | -97.70% | -138.40% | -67.98% |
| Earnings Yield | -351.76% | -594.89% | -4391.30% | -141.76% | -36.35% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -8.38 | -72.96 | -330.36 | -127.91 | -109.38 |
| Free Cash Flow Per Share | -8.38 | -72.96 | -330.36 | -127.91 | -109.38 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -2208541.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -2208541.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -361.02% | -540.45% | -3610.46% | -130.31% | -26.19% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.28 | -0.17 | -0.02 | -0.71 | -2.75 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.35 | 1.32 | 0.03 | 1.13 | 2.15 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.28 | -0.19 | -0.03 | -0.77 | -3.82 |
| Price-to-Operating Cash Flow Ratio | -0.28 | -0.19 | -0.03 | -0.77 | -3.82 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.00 | -0.00 | 0.08 | 0.03 |
| Enterprise Value Multiple | 0.69 | 0.09 | -29.37 | -0.06 | -1.39 |
| Enterprise Value | -5.37M | -1.10M | -7.26M | 538.22K | 10.94M |
| EV to EBITDA | 0.69 | 0.09 | -29.37 | -0.06 | -1.39 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 0.69 | 0.10 | 1.13 | -0.06 | -1.92 |
| EV to Operating Cash Flow | 0.69 | 0.10 | 1.13 | -0.06 | -1.92 |
| Tangible Book Value Per Share | 6.72 | 10.20 | 327.58 | 87.19 | 194.17 |
| Shareholders’ Equity Per Share | 6.72 | 10.20 | 327.58 | 87.19 | 194.17 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -8.16 | -80.31 | -401.80 | -139.16 | -151.82 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.97 | 1.00 | 1.00 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.03 | 0.91 | 0.82 | 0.92 | 0.72 |
Currency in USD
